MiNK Therapeutics Q1 EPS $(0.23) Misses $(0.21) Estimate

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent.

byBenzinga Newsdesk

May 10, 2022

1 minute read

MiNK Therapeutics (NASDAQ:INKT) reported quarterly losses of $(0.23) per share which missed the analyst consensus estimate of $(0.21) by 9.52 percent.

The Grand Plan For Ethereum: An Analysis Of Zero-Knowledge Scaling From ETHDenver 2023

By Ryan McNamara

Today, 8:41 AM

Without a high-level understanding of zero-knowledge (ZK) technology running on the Ethereum Virtual Machine (EVM), it’s hard to conceptualize the benefit this innovation brings to the crypto economy.

ETH

News

White House National Security Advisor Jake Sullivan Says White House Is Very Pleased With Candor, Substance And Intensity Of Discussions On Chips Concerns; U.S. Had Consultations With Its Partners Including Japan And The Netherlands On Chip Restriction…

By Benzinga Newsdesk

Today, 8:41 AM

-sullivan

EWJ

Zosano Pharma Late Tuesday Priced 1.25M Unit Public Offering of Common Stock and Warrants @$0.30/Unit

By Charles Gross

Today, 8:41 AM

Zosano Pharma Corporation (Nasdaq: ZSAN), a clinical-stage biopharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 51,250,000 units, each consisting of one share of common stock and one warrant to purchase one share of common stock, at a public offering price of $0.30

ZSAN